DIA Stock Overview
Engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for DIA from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
DiaSorin S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €91.04 |
| 52 Week High | €112.35 |
| 52 Week Low | €88.96 |
| Beta | 0.31 |
| 1 Month Change | -7.78% |
| 3 Month Change | -9.68% |
| 1 Year Change | -9.64% |
| 3 Year Change | -24.70% |
| 5 Year Change | -47.53% |
| Change since IPO | 635.38% |
Recent News & Updates
Recent updates
DiaSorin's (BIT:DIA) Upcoming Dividend Will Be Larger Than Last Year's
Mar 20
Is DiaSorin (BIT:DIA) Using Too Much Debt?
Mar 16
MeMed, LIAISON PLEX, And Global Expansion Set To Boost Revenue And Earnings Growth
Strong hospital strategy and new product offerings in the U.S. could drive significant revenue growth and new hospital additions.Is DiaSorin (BIT:DIA) A Risky Investment?
Nov 29DiaSorin S.p.A. (BIT:DIA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 08DiaSorin S.p.A. (BIT:DIA) Investors Are Less Pessimistic Than Expected
Aug 23DiaSorin S.p.A. (BIT:DIA) Just Released Its Interim Results And Analysts Are Updating Their Estimates
Aug 01We Think DiaSorin (BIT:DIA) Can Stay On Top Of Its Debt
Jul 16Shareholder Returns
| DIA | IT Medical Equipment | IT Market | |
|---|---|---|---|
| 7D | -2.1% | -1.6% | -0.5% |
| 1Y | -9.6% | -5.3% | 15.3% |
Return vs Industry: DIA underperformed the Italian Medical Equipment industry which returned -5.3% over the past year.
Return vs Market: DIA underperformed the Italian Market which returned 15.3% over the past year.
Price Volatility
| DIA volatility | |
|---|---|
| DIA Average Weekly Movement | 3.6% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in IT Market | 8.7% |
| 10% least volatile stocks in IT Market | 3.4% |
Stable Share Price: DIA has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: DIA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 3,279 | Carlo Rosa | int.diasorin.com |
DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic LIAISON chemiluminescence analyzers under LIAISON XL and LIAISON XS name; and Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. The company was founded in 1968 and is headquartered in Saluggia, Italy.
DiaSorin S.p.A. Fundamentals Summary
| DIA fundamental statistics | |
|---|---|
| Market cap | €4.94b |
| Earnings (TTM) | €194.11m |
| Revenue (TTM) | €1.21b |
Is DIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIA income statement (TTM) | |
|---|---|
| Revenue | €1.21b |
| Cost of Revenue | €415.21m |
| Gross Profit | €794.22m |
| Other Expenses | €600.11m |
| Earnings | €194.11m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 31, 2025
| Earnings per share (EPS) | 3.60 |
| Gross Margin | 65.67% |
| Net Profit Margin | 16.05% |
| Debt/Equity Ratio | 39.9% |
How did DIA perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/28 17:24 |
| End of Day Share Price | 2025/05/28 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DiaSorin S.p.A. is covered by 29 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sumit Sayal | AlphaValue |
| Paola Saglietti | Banca Akros S.p.A. (ESN) |
| Gaurav Jain | Barclays |